Identification and evaluation of the inhibitory effect of Prunella vulgaris extract on SARS-coronavirus 2 virus entry

Zhujun Ao; Mable Chan; Maggie Jing Ouyang; Titus Abiola Olukitibi; Mona Mahmoudi; Darwyn Kobasa; Xiaojian Yao

doi:10.1371/journal.pone.0251649

Abstract

Until now, antiviral therapeutic agents are still urgently required for treatment or prevention of SARS-coronavirus 2 (SCoV-2) virus infection. In this study, we established a sensitive SCoV-2 Spike glycoprotein (SP), including an SP mutant D614G, pseudotyped HIV-1-based vector system and tested their ability to infect ACE2-expressing cells. Based on this system, we have demonstrated that an aqueous extract from the Natural herb Prunella vulgaris (NhPV) displayed potent inhibitory effects on SCoV-2 SP (including SP_G614 mutant) pseudotyped virus (SCoV-2-SP-PVs) mediated infections. Moreover, we have compared NhPV with another compound, Suramin, for their anti-SARS-CoV-2 activities and the mode of their actions, and found that both NhPV and Suramin are able to directly interrupt SCoV-2–SP binding to its receptor ACE2 and block the viral entry step. Importantly, the inhibitory effects of NhPV and Suramin were confirmed by the wild type SARS-CoV-2 (hCoV-19/Canada/ON-VIDO-01/2020) virus infection in Vero cells. Furthermore, our results also demonstrated that the combination of NhPV/Suramin with an anti-SARS-CoV-2 neutralizing antibody mediated a more potent blocking effect against SCoV2-SP-PVs. Overall, by using SARS-CoV-2 SP-pseudotyped HIV-1-based entry system, we provide strong evidence that NhPV and Suramin have anti-SARS-CoV-2 activity and may be developed as a novel antiviral approach against SARS-CoV-2 infection.

Citation: Ao Z, Chan M, Ouyang MJ, Olukitibi TA, Mahmoudi M, Kobasa D, et al. (2021) Identification and evaluation of the inhibitory effect of Prunella vulgaris extract on SARS-coronavirus 2 virus entry. PLoS ONE 16(6): e0251649. https://doi.org/10.1371/journal.pone.0251649

Editor: Shan Cen, China Academy of Chinese Medical Sciences, CHINA

Received: January 20, 2021; Accepted: April 29, 2021; Published: June 9, 2021

Copyright: © 2021 Ao et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Data Availability: All relevant data are within the paper.

Funding: This work was supported by Canadian 2019 Novel Coronavirus (COVID-19) Rapid Research Funding (OV5-170710) by Canadian Institute of Health Research (CIHR) and Research Manitoba. Dr. X-j Y holds a Manitoba Research Chair Award from the Research Manitoba. O.T.A is the recipient of PhD scholarship from the Research Manitoba/Manitoba Institute of Child Health. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing interests: The authors have declared that no competing interests exist.

Introduction

The recent and ongoing outbreak of Coronavirus disease 2019 (COVID-19) has called for serious and urgent global attention [1, 2]. The COVID-19 disease is caused by a newly emerged virus strain of Severe Acute Respiratory Syndrome (SARS) known as SARS-CoV-2 [1]. Although the case fatality ratio (CFR) of COVID-19 can only be detected at the end of the outbreak, an estimated global CFR was calculated to be 5.5–5.7% in March 2020 shockingly more than the seasonal influenza outbreak [3]. While in August 2020, the infection fatality ratio was estimated by WHO to be 0.5–1% [4]. Since the identification of the SARS-CoV-2 sequences [5], extensive efforts worldwide have been focused on developing effective vaccines and antiviral drugs against SARS-CoV-2 with the hope to rapidly and efficiently control this new human coronavirus (CoV) infection.

SARS-CoV-2 belongs to a betacoronavirus subfamily that includes enveloped, large and positive-stranded RNA viruses responsible for causing severe respiratory system, gastrointestinal and neurological symptoms [6–9]. The human CoV was first identified in 1960 and constituted about 30% of the causes of the common cold. Among the identified human CoVs are NL63, 229E, OC43, HKU1, SARS-CoV, the Middle East respiratory syndrome (MERS)-CoV, and SARS-CoV-2 [10, 11]. A recent study has revealed that SARS-CoV-2 was closely related (88% identity) to two SARS-like CoVs that were isolated from bats in 2018 in China, but it was less related to SARS-CoV (79%) and MERS-CoV (about 50%) [12]. The key determinant for the infectivity of SARS-CoV-2 depends on the host specificity with the viral surface-located trimeric spike (S) glycoprotein (SP), which is commonly cleaved by host proteases into an N-terminal S1 subunit and a membrane-embedded C-terminal S2 region [13]. Recent studies revealed that an SP mutation, Aspartic acid (D) changed to Glycine (G) at amino acid position 614, in the S1 domain has been found in high frequency (65% to 70%) in April to May of 2020, that was associated with an increased viral load and significantly higher transmission rate in infected individuals, but no significant change with disease severity [14]. The following studies also suggested that G614 SP mutant pseudotyped retroviruses infected ACE2-expressing cells markedly more efficiently than those with D614 SP [15].

Up till now, several compounds have been tested in numerous clinical trials, including remdesivir, lopinavir, umifenovir, and hydroxychloroquine [16–20]. Moreover, some in vitro research suggested that other drugs such as fusion peptide (EK1), anti-inflammatory drugs (such as hormones and other molecules) could be potentially used in the treatment of SARS-CoV-2 disease (reviewed in [21, 22]). However, their safety and efficacy have not been confirmed by clinical trials. Currently, specific antiviral treatment drugs are still not available for SARS-CoV-2 infections [22].

Traditional Natural medicine holds a unique position among all conventional medication because of its usage over hundreds of years of history. Many aqueous extracts of traditional natural medicinal herbs have been proven to have antiviral activities [23], and most of these are generally of low toxicity, cheap and readily accessible. As an easily free and low-cost natural source, they are incredibly valuable as potential new sources for rapid responses against the ongoing COVID-19 pandemic. Prunella vulgaris, widely distributed in China, Europe, northwestern Africa and North America, is known as a self-heal herb. Studies have previously found that a water-soluble substance from Natural herb Prunella vulgaris (NhPV) exhibits significant antiviral activity against HIV, HSV and Ebola virus [24–27]. However, whether NhPV can block SARS-CoV-2 virus infection is unknown. Another compound, Suramin, has also been previously shown to be a potent inhibitor against HIV [28], while the subsequent studies revealed that its inhibitory effects on HIV replication did not correlate with clinical or immunologic improvement [29, 30]. A previous study observed that Suramin not only substantially reduced viral loads of chikungunya virus (CHIKV) in infected mice, but it also ameliorated virus-induced foot lesions in the mice [31]. Recently, Salgado-Benvindo C. et al. reported that Suramin can inhibit SARS-CoV-2 infection in cell culture by interfering with early steps of the replication cycle [32].

In this study, we have established a highly sensitive SARS-CoV-2 SP-pseudotyped virus (SCoV-2 SP-PVs) system and investigated the impact of the cytoplasmic tail and a G614 mutant of SP on virus entry ability. We also examined two compounds, NhPV or Suramin, for their blocking activities in the SCoV-2 SP-PVs system and SARS-CoV-2 infection, and the antiviral mechanism of their actions. Furthermore, we investigated the synergistic effect of combining anti-SARS-CoV-2 neutralizing antibody (nAb) with NhPV or Suramin to enhance their anti-SARS-CoV-2 activity. Overall, this study provides evidence for the first time that NhPV, an aqueous extract from Prunella vulgaris, has potent anti- SARS-CoV-2 activity.

Materials & methods

Plasmid constructs

The SARS-CoV-2 expressing plasmids (pCAGGS-nCoVSP, pCAGGS-nCoVSPΔC and pCAGGS-nCoVSPΔC_G614) contain SARS-CoV-2 SP transgene (GenBank accession No. MN908947) or corresponding mutated genes for SPΔC and ΔC_G614. The SPΔC and ΔC_G614 were generated by mutagenic PCR technique. Primers are following: SPΔC-3’primer, 5_GCAGGTACCTAGAATTTGCAGCAGGATCCAC; D614G-5’, 5_GCTGTTCTTTATCAGGGTGTTAACTGCACAG; D614G-3’, 5_CTGTGCAGTTAACACCCTGATAAAGAACAGC. Mutated genes were cloned into the pCAGGS plasmid, and each mutation was confirmed by sequencing. The HIV vector encoding for Gaussia luciferase gene HIV-1 RT/IN/Env tri-defective proviral plasmid (ΔRI/E/Gluc) and the helper packaging plasmid pCMVΔ8.2 encoding for the HIV Gag-Pol plasmids are described previously [25, 33].

Cell culture, antibodies and chemicals

The human embryonic kidney cells (HEK293T) and kidney epithelial cells (VeroE6 and Vero cells (ATCC, CCL-81)) from African green monkeys were cultured in Dulbecco’s modified Eagle’s medium (HEK293T, VeroE6) or Minimum Essential Medium (MEM.; Vero). HEK293T expressing ACE2 (293T_ACE2) was obtained from GeneCopoeia Inc, Rockville, MD. All cell lines were supplemented with 10% fetal bovine serum (F.B.S.), 1X L-Glutamine and 1% penicillin and streptomycin. The rabbit polyclonal antibody against SARS-CoV-2 SP (Cat# 40150-R007) and ACE2 protein (Cat# 40592-T62) were obtained from Sino Biological and anti-HIVp24 monoclonal antibody was described previously [34, 35]. The HIV-1 p24 ELISA Kit was obtained from the AIDS Vaccine Program of the Frederick Cancer Research and Development Center. SARS-CoV-2 SP-ACE2 binding ELISA kit (Cat# COV-SACE2-1) was purchased from RayBio. Anti-SARS-CoV-2 neutralizing Antibody (nAb) Human IgG1(SAD-535) was purchased from ACRO Biosystems. AH0109 was described previously [36].

Preparation and purification of herb extracts of Natural herb Prunella vulgaris (NhPV)

The dried fruitspikes of Prunella vulgaris (Fig 3A) were first soaked overnight in deionized water at room temperature and then boiled for one hour. Then the cooled supernatant was centrifuged (3000 g, 30 min), filtered through a 0.45 μm cellulose acetate membrane and finally lyophilized, as described previously [24]. The resulting dark brown residue was dissolved in deionized water and stored at -20°C. A single symmetrical peak corresponding to a molecular weight of polysaccharides (approximately 10 kDa) in the aqueous extract from NhPV was detected by HPLC analysis, as described previously [24]. Suramin (Cat# sc-200833) was purchased from Santa Cruz BioTech and was dissolved in sterile H2O and stored at -20°.

Virus production, infection and inhibition experiments

SARS-CoV-2 SP or S.P. ΔC pseudotyped viruses (SCoV-2-SP-PVs, SCoV-2-SPΔC-PVs, SCoV-2-SPΔC_G614-PVs) were produced by transfecting HEK293T cells with pCAGGS-SARS-CoV-2-SP, pCAGGS-SARS-CoV-2-SPΔC, or pCAGGS-SARS-CoV-2-SPΔC_G614, pCMVΔ8.2 and a Gluc expressing HIV vector ΔRI/E/Gluc. After 48 hrs of transfection, cell culture supernatants were collected and pseudotyped VLP.s were purified from the supernatant by ultracentrifugation (32,000 rpm) for 2 hrs. The pelleted VPs were resuspended into RPMI medium and virus titers were quantified using an HIV-1 p24 ELISA assay. The SARS-CoV SP-pseudotyped ^Luc+MLV was produced as described previously [37]. Briefly, 293T cells were transfected with a SARS-CoV S.P. expressing plasmids (pcDNA-SARS-S), pCMV-MLVgagpol MLV plasmid, and pTG-Luc transfer vector. After 48 hrs of transfection, the supernatants were harvested and ready for infection experiments. The wild type SARS-CoV-2 (hCoV-19/Canada/ON-VIDO-01/2020, GISAID accession# EPI_ISL_425177) was propagated and produced in Vero cells (ATCC, CCL-81).

To investigate the infection ability of SCoV-2-SP-VPs, the same amount of each SCoV-2-SP-PV stock (as adjusted by p24 levels) were used to infect different target cells at 0.4 x 10⁵ cells per well (24 well plate) for 3 hrs and washed. After 48 or 72 hrs, the supernatants were collected and the viral infection rate was evaluated by measuring Gaussia luciferase (Gluc) activity. Briefly, 50ul of Coelenterazine substrate (Nanolight Technology) was added to 20ul of supernatant, mixed well and read in the luminometer (Promega, U.S.A.).

To evaluate the anti-SARS-CoV-2 SP-mediated entry activity of NhPV or Suramin, various concentrations of herb extract or compound were directly added into target cells at different time points before or after infection, as indicated. After 3hrs of infection at 37°C, the cells were washed once to remove excessive residue viruses/compound and cultured in fresh medium. The anti-SARS-CoV-2 effects of NhPV or Suramin were evaluated by measuring the Gluc activity or p24 levels in the supernatant infected cultures.

Efficacy of NhPV or Suramin against SARS-CoV-2 (hCoV- 19/Canada/ON-VIDO-01/2020, GISAID accession# EPI_ISL_425177) was evaluated in Vero cells. The Vero cells were seeded into 96-well plates and reached a confluency of 90% at the second day. Then each compound was diluted in assay medium (DMEM with 1X penicillin-streptomycin) and added to the wells (100 ul/well), followed by adding 100 μL of SARS-CoV-2 at a MOI of 0.01, resulting in a final 1X drug concentrations. As positive controls, wells without drugs were infected with SARS-CoV-2 at the same MOI. After 4 hrs of infection, cells were washed and fresh medium (MEM containing 1% FBS., L-Glutamine, and penicillin-streptomycin and the same concentrations of compound) was added to the cells. Cytopathic effect (C.P.E.) was monitored in each well at 48 to 72 hours post-infection (hpi). Viral replication levels were titrated by TCID₅₀ assay using supernatants collected at 48hpi. Supernatants were serially diluted 1:10, 100 μL of each dilution was added to 96-well plates of Vero cells in triplicate, plates were incubated at 37°C with 5% CO₂ and the presence of CPE was determined 4 days pi. The TCID50/mL titer was determined using the Reed and Muench method.

COVID-19 spike protein-ACE2 binding assay

The inhibitory effect of NhPV or Suramin on the interaction of SP-ACE2 was tested with COVID-19 Spike-ACE2 binding assay kit. Briefly, 96-well plate was coated with recombinant SARS-CoV-2 Spike protein. NhPV or Suramin was then added to the wells for 10 min followed by adding recombinant human ACE2 protein. After incubation for 3 hours, wells were washed three times and a goat anti-ACE2 antibody that binds to the Spike-ACE2 complex was added followed by applying the HRP-conjugated anti-goat IgG and 3,3’,5,5’-tetramethylbenzidine (TMB.) substrate. The intensity of the yellow color is then measured at 450 nm.

Western blot (WB) analyses

To detect cellular protein ACE2, SARS-CoV-2-SP, or SPΔC in transfected cells or SCoV-2-SP-VPs, transfected 293T_ACE2 cells or VPs were lysed in RIPA buffer, and directly loaded into the 10% SDS–PAGE gel and the presence of each protein was detected by WB with various corresponding antibodies.

Cytotoxicity assay

The trypan blue assay was used to determine the effect of NhPV or Suramin on the cell viability and cytotoxicity. Briefly, Vero E6 or 293T_ACE2 cells were cultured at a density of 1–1.5×10⁴ cells/well in a 96-well format in the presence of various concentrations of NhPV or Suramin for 3hrs, then cells were washed and added with fresh medium. At 48 hours, the cell Viability was tested by trypan blue assay.

Statistical analysis

Statistical analysis of the infection levels of SARS-CoV-2-SP, or SPΔC-VPs and the inhibition effect of NhPV or Suramin were performed using the unpaired t-test (considered significant at P≤0.05) by GraphPad Prism 6.01 software.

Results

Generation of a SARS-CoV-2 SP-pseudotyped HIV-1-based entry system

Since previous studies have reported that a carboxyl-terminal truncation of 17 amino acids of SARS SP substantially increased SARS SP-mediated cell-to-cell fusion [38], we have constructed a full length SP (SARS-CoV-2-SP) and the C-terminal 17 amino acid (aa) deletion SP (SARS-CoV-2-SPΔC) expressing plasmids (Fig 1A(a, b)). The SARS-CoV-2-SP-mediated virus entry system was established by co-transfecting SARS-CoV-2 SP or SARS-CoV-2-SPΔC expressing plasmid(s), a HIV-based vector (ΔRI/ΔEnv/Gluc) in which viral reverse transcriptase/integrase deleted/envelope gene partially deleted and encoded a Gaussia luciferase gene in the nef position [33], and a packaging plasmid (pCMVΔR8.2) in HEK293T cells (Fig 1B). The Gaussia luciferase (Gluc) is a bioluminescent enzyme that can be secreted into the media, enabling the analysis of viral expression by direct measurement of Gluc activity in the supernatant.

Download:

Fig 1. Generation of SARS-CoV2-SP-pseudotyped lentivirus particles (SCoV-2-SP-PVs).

A) Schematic representation of SARS-CoV-2SP, SARS-CoV-2SPΔC, and SARS-CoV-2SP_G614ΔC expressing plasmids. B) Schematic representation of plasmids and procedures for production of SARS-CoV2-SP-pseudotyped lentivirus particles (SCoV-2-SP-PVs). C) Detection of SARS-CoV-2 SPs and HIV p24 protein expression in transfected 293T cells and viral particles by WB with anti-SP or anti-p24 antibodies. D) Different amounts of SCoV-2-SP-PVs and SCoV-2-SPΔC-PVs virions (adjusted by p24) were used to infect 293T_ACE2 cells. At different time intervals, the Gaussia Luciferase activity (Gluc) (left panel) and PVs-associated p24 (at 72 hrs) in supernatants was measured. Statistical significance was determined using unpaired t-test, and significant p values are represented with asterisks, *≤0.05.

https://doi.org/10.1371/journal.pone.0251649.g001

The expression and incorporation of SARS-CoV-2 SPs or SARS-CoV-2 SPΔC in the cells and the pseudotyped viruses (SP-PVs, or SPΔC-PVs), were analyzed by SDS-PAGE and Western blot (WB) with a mouse anti-SP antibody, as indicated in Fig 1C. As expected, the HIV capsid Gagp24 protein was detected in all of the cell lysates and the pelleted SP-PVs and SPΔC-PVs by rabbit anti-p24 antibodies (Fig 1C, lower panel). The SARS-CoV-2 SP including S1/S2 was clearly detected in both SARS-CoV-2-SPs and SARS-CoV-2-SPΔC-transfected cells (Fig 1C, lanes 1 and 2). Interestingly our results revealed that virus-incorporation level of SARS-CoV-2 SPΔC were significantly higher than that of SARS-CoV-2-SP (Fig 1C, compare lane 4 to 3).

To test the infectivity of generated pseudoviruses, we infected 293T-ACE2 cells with serial diluted amounts (25, 12.5, 6.25ng of p24) of SP-PVs or SPΔC-PVs for 3 hrs. The Gluc activities or Gagp24 of supernatants from infected cells were measured at 24h, 48h or 72h post infection. The results showed that both SP-PVs and SPΔC-PVs infected 293T-ACE2 cells and induced an increase of Gluc activity in the supernatants in a dose dependent manner (Fig 1D, left panel). As expected, the infectivity of SPΔC-PVs was significantly higher than that of SP-PVs. The infection of pseudoviruses in 293T_ACE2 cells was further confirmed by detection of the HIVp24 levels in the supernatants of infected cells through ELISA assay (Fig 1D, right panel).

To test whether the infection is ACE2-dependent, we infected various cell lines, including HEK293T, 293T_ACE2 and VeroE6 with SP-PVs and SPΔC-PVs, respectively. The results showed that these pseudoviruses was able to efficiently infect 293T_ACE2 cells, has lower level of infection in VeroE6 cells, but could not infect HEK293T (Fig 2A). In parallel, we detected high level expression of the SARS-CoV-2 receptor ACE2 in 293T_ACE2 cells (Fig 2B).

Download:

Fig 2. SARS-CoV-2 SP-PVs’s infection in different cell lines and SARS-CoV-2 SP_G416 variant exhibited stronger virus entry.

A) 293T_ACE2, 293T, and Vero-E6 cells were infected by equal amounts of SARS-CoV-2SP- or SARS-CoV-2SPΔC-pseudotyped viruses (PVs), or mock-infected (MOCK). At 48 hrs pi, the Gluc activity in supernatants was measured. B) The expression of SARS-CoV-2SP receptor, ACE2 in 293T and 293T_ACE2 cells detected by WB with anti-ACE2 antibodies. C) Detection of SARS-CoV-2 SPΔC, SPΔC_G614 and HIV p24 protein expressions in transfected 293T cells and viral particles by WB with corresponding antibodies. D) Infectivity comparison of SPΔC _D614-PVs and SPΔC_G614-PVs in 293T_ACE2 cells. Equal amounts of SPΔC_D614-PVs and SPΔC_G614-PVs virions (adjusted by p24 level) were used to infect 293T_ACE2 cells. At different days post-infection (pi), Gluc activity in supernatants was measured. The results are the mean ±SD of duplicate samples, and the data are representative of results obtained in two independent experiments. E) The SPΔC_G614-GFP⁺PVs were produced from 293T cells and used to infect 293T_ACE2 cells in 96-well plate After 48 hrs pi, GFP-positive cells (per well) were counted and photographed by fluorescence microscope (on the top of the panel). Statistical significance was determined using unpaired t-test, and significant p values are represented with asterisks, *≤0.05, **≤0.01.

https://doi.org/10.1371/journal.pone.0251649.g002

SARS-CoV-2 SP G416 variant exhibited more efficient virus entry

Recent sequence analyses revealed a SP mutation, Aspartic acid (D) changed to Glycine (G) at aa position 614, was found in high frequency (65% to 70%) in April to May of 2020, indicating a transmission advantage to D614 [14]. In this study, we have also generated constructs to express SCoV-2-SPΔC_G614 (Fig 1A(c)) and compared its virus entry ability with SCoV-2-SPΔC (SPΔC_D614). Our results showed that SCoV-2-SPΔC_G614 was incorporated into viruses similar to SCoV-2-SPΔC_D614 (Fig 2C, compare lane 5 to lane 4), however, the SARS-CoV2-SPΔC_G614-pseudotyped viral particles (SPΔC_G614-PVs) mediated approximately 3-fold higher infection than that of SPΔC_D614-PVs (Fig 2D), suggesting that the SP_G614 mutation increases SP-mediated viral entry.

In addition, we have generated a GFP⁺ SARS-CoV-2-SP-mediated virus entry system by co-transfecting SARS-CoV-2 SPΔC_G614, a lentiviral vector that expressing GFP, and the pCMVΔR8.2 in HEK293T cells and produced SPΔC_G614-PVs expressing GFP (GFP⁺ SPΔC_G614-PVs). After 293T_ACE2 cells were infected with GFP⁺ SPΔC_G614-PVs, the GFP positive 293T_ACE2 cells were clearly detected under fluorescent microscopy (Fig 2E). All of data indicates that both Gluc+, GFP-expressed SARS-CoV-2-SP-pseudotyped virus infection systems can be very sensitive system for studying the functions of SARS-CoV-2-SP variants.

Evaluation of NhPV and Suramin for blocking SARS-CoV2-SP-mediated virus entry

Next we tested whether NhPV (Fig 3A) and Suramin could block SARS-CoV2 SP-mediated virus entry of 293T_ACE2 cells since both NhPV and Suramin have been previously reported to exhibit the antiviral activities against several viral infections [24–28, 31]. Briefly, 293T_ACE2 cells were infected with SPΔC-PVs in the presence of different concentrations (25, 50, 75, 100 and 200ug/ml) of NhPV (Fig 3B, left panel) or Suramin (Fig 3B, right panel), respectively. After 3 hour of infection, the infected cells were washed to remove the viruses and compounds and cultured with fresh medium. At 48 hrs post-infection, the supernatants were collected and the virus-produced Gluc activities were measured for monitoring the infection levels. Consistent with our previous observation [25], we did not detect any toxic effect on either 293T_ACE2 cells or Vero E6 cells for 3hs exposure to NhPV, nor to Suramin (Fig 3C). Significantly, both NhPV and Suramin were able to inhibit SARS-CoV-2-SP-pseudotyped virus infection. The half maximal inhibitory concentration (IC50) of NhPV was 30 ug/ml (Fig 3B, left panel), while IC50 of Suramin was about 40 ug/ml (Fig 3B, right panel). The inhibitory effect of NhPV and Suramin on a SP mutant pseudotyped virus (SPΔC_G614-PVs) infection was also tested, and results show that SPΔC_G614-PVs infection is also susceptible to NhPV and suramin (Fig 3D). Meanwhile, the SARS-CoV-2-SPΔC_G614 pseudotyped GFP+ virus infection was monitored in the presence of NhPV or Suramin and results showed that the pseudotyped GFP+ virus infection was efficiently inhibited by the presence of NhPV and Suramin (Fig 3E). Furthermore, we also tested the inhibitory effects of NhPV and Suramin on severe acute respiratory syndrome coronavirus (SARS-CoV) spike protein-mediated infection by using a SARS-CoV SP-pseudotyped MLV infection system, as described previously [37]. Results showed that both NhPV and Suramin block SARS-CoV SP-mediated infection in 293T-ACE2 cells (Fig 3F). All of these results demonstrate that both NhPV and Suramin exhibit strong inhibitory effect on infections mediated by SPΔC_D614-PVs, SPΔC_G614-PVs and SARS-CoV SP-PVs.

Download:

Fig 3. Both SARS-CoV-2 SP- and SARS-CoV SPΔC_G614-PV’s infection was efficiently blocked by NhPV and Suramin.

A) Images of the dried Prunella Vulgaris flowers and its water extract (NhPV). B) The analysis of anti-SARS-CoV-2 activities of NhPV or Suramin. 293T_ACE2 cells were infected by equal amounts of SARS-CoV-2SPΔC-pseudotyped viruses in the presence of different dose of NhPV or Suramin. At 48 hrs pi, the Gluc activity in supernatants was measured. (% inhibition = 100 x [1 - (Gluc value in presence of drug)/(Gluc value in absence of drug)). C) The cytotoxicity analysis of NhPV and Suramin in 293T_ACE2 cells and VeroE6 cells. 293T_ACE2 cells or VeroE6 cells in 96 well plates were treated with different concentration of NhPV or Suramin for 3hrs, compounds were washed and replaced by fresh medium. At 48 hours, the cell Viability was tested by trypan blue assay. D) Infection inhibition of NhPV or Suramin on SARS-CoV-2-SPΔC_G614-PVs in 293T_ACE2 cells. Equal amounts of SCoV-2-SPΔC_G614-PVs (adjusted by p24 level) were used to infect 293T_ACE2 cells in presence of different concentrations of NhPV or Suramin, in indicated at bottom of the panel. At 48 hrs pi, Gluc activity in supernatants was measured and present as % inhibition. Means ±S.D. were calculated from duplicate experiments. E) 293T_ACE2 cells in 96-well plate were infected with SP△C_G614-GFP⁺ PVs. After 48 hrs pi, GFP-positive cells (per well) were counted (left panel) and photographed by fluorescence microscope (top panel, a. Without drugs; b. Without infection; c. In the presence of NhPV (100 μg/ml); d. In the presence of Suramin (100 μg/ml). F) 293T_ACE2 cells in 96-well plate were infected with SARS-CoV SP-pseudotyped ^Luc+ MLV. At 48 hrs pi, the infected cells were lysed and cell-associated luc activity was measured and calculated as % inhibition (% inhibition = 100 x [1 - (Luc value in presence of drug)/(Luc value in absence of drug)). The results are the mean ±SD of duplicate samples, and the data are representative of results obtained in two independent experiments.

https://doi.org/10.1371/journal.pone.0251649.g003

Mechanistic analyses of actions of NhPV and Suramin against SARS-CoV-2-SP-mediated virus entry

To gain more insight into the mechanism of how NhPV or Suramin targets SARS-CoV-2 SP-PVs infection, each of the drugs (100 μg/ml) was added to 293T_ACE2 cells at various time points during the infection, as indicated in Fig 4. After 48 hrs of infection, the supernatants were collected and measured for virus-expressed GLuc activity. Results showed that a strong inhibitory effect was achieved when cells were pretreated with NhPV or Suramin one hour before infection or when the compounds were present simultaneously with SPΔC_G614-PVs (Fig 4A and 4B). Interestingly, even when drug was added at one hour post-infection, NhPV still exhibited nearly 70% inhibition on SPΔC_G614-PVs infection (Fig 4A), while for Suramin, a lower inhibitory effect (about 30% inhibition) was also observed (Fig 4B). When NhPV or Suramin was added to culture after 3 hrs of infection, no inhibitory activity on viral infection was observed (Fig 4A and 4B). These results suggest that both NhPV and Suramin act on the entry step of SPΔC_G614-PVs infection.

Download:

Fig 4. Characterization of the mechanisms of NhPV and Suramin for their anti-SARS-CoV-2-SP action.

A) Time-dependent inhibition of SPΔC_G614-PVs infection mediated by NhPV or Suramin. NhPV (100 μg/mL) or Suramin (100 μg/mL) was added at 1 hr prior to infection, during infection (0 hr), and at 1 hr, and 3 hr pi. The positive controls (P.C.) were 293T_ACE2 cells infected with SPΔC_G614-PVs in the absence of compounds. At 3 hrs pi, all of the cell cultures were replaced with fresh DMEM and cultured for 48 hrs. Then, the Gluc activity was monitored in the supernatant, and the data are shown as a percentage of inhibition (%). B) Inhibitory effect of NhPV or Suramin on SARS-CoV2-SP/ACE2 binding by ELISA as described in materials and methods. nAB: anti-COVID-19 neutralizing antibody (SAD-S35). The results are the mean ±S.D. of duplicate samples, and the data are representative of results obtained in two independent experiments.

https://doi.org/10.1371/journal.pone.0251649.g004

To further determine whether NhPV or Suramin is targeting the interaction of SARS-CoV2-SP and its receptor, ACE2, we used an in vitro SARS-CoV2-SP/ACE2 binding ELISA assay, as described in Materials and methods. Additionally, an anti-COVID-19 neutralizing antibody (SAD-S35) [39] was included in parallel. Results revealed that the presence of either NhPV or Suramin was able to specifically target and significantly reduce the SARS-CoV2-SP-ACE2 interaction (Fig 4C and 4D). It should be noted that the neutralizing antibody (SAD-S35) also showed a strong inhibition on SARS-CoV2-SP/ACE2 interaction (Fig 4C and 4D).

Combination of NhPV and anti-SARS-CoV-2 neutralizing antibody (SAD-S35) mediated more potent blocking effect against SARS-CoV2-SP-PVs

As described above, both NhPV and Suramin can inhibit SARS-CoV2-SP/ACE2 interaction and SP-PVs infection. We thus tested whether the combination of two compounds could mediate a stronger anti-SARS-CoV-2 activity. 293T_ACE2 cells were infected with SPΔC_G614-PVs in the presence of a cocktail of NhPV/Suramin (25 μg/mL per compound), or NhPV (50 μg/mL) or Suramin (50 μg/mL) alone. The results showed that in the presence of a cocktail of NhPV/Suramin, SPΔC_G614-PVs was inhibited to 78%, while in the presence of NhPV or Suramin alone, inhibition rate was 65% or 40% (Fig 5A). These results suggest that a combination of these two compounds may be able to achieve more efficient inhibition against SARS-CoV-2 infection.

Download:

Fig 5. Enhanced inhibitory effects mediated by combination of NhPV and Suramin with neutralizing antibody (SAD-S35).

A) 293T_ACE2 cells were infected with SPΔC_G614-PVs in presence of NhPV (50μg/ml) or suramin (50μg/ml) alone or a mix of NhPV and suramin (each with 25μg/ml). The Gluc activity in the supernatant was measured after 48 hrs and present as % inhibition. B) Inhibitory effect of nAb SAD-S35 on SPΔC_G614-PVs infection. 293T_ACE2 cells were infected with SPΔC_G614-PVs in the presence of serially diluted SAD-S35 (1.25 to 10 μg/ml) for 3 hrs. Then infected cells were cultured in fresh medium. At 48 hrs pi., the Gluc activities in the supernatants were measured and presented as % inhibition. C) 293T_ACE2 cells were infected with SPΔC_G614-PVs in the presence of serially diluted SAD-S35 (0.625 to 2.5 μg/ml) alone or mixed with NhPV (25 μg/mL) or Suramin (25 μg/mL) for 3 hrs and the infected cells were cultured in fresh medium. At 48 hrs pi., the Gluc activities in the supernatants were measured and presented as % inhibition. The results are the mean ± S of duplicate samples, and the data are representative of results obtained in two independent experiments. Statistical significance was determined using unpaired t-test between NhPV+Ab/Ab or Suramin +Ab/Ab, and significant p values are represented with asterisks, *≤0.05, **≤0.01.

https://doi.org/10.1371/journal.pone.0251649.g005

The anti-SARS-CoV-2 neutralizing antibody (SAD-S35) was also tested and showed a does-dependent neutralizing activity against SPΔC_G614-PVs with an IC50 of 2.4 μg/mL (Fig 5B). Next, we sought to determine whether the combination of NhPV or Suramin with SAD-S35 could mediate a stronger anti-SARS-CoV-2 activity. Thus, serially diluted SAD-S35 (0.625 to 2.5 μg/ml) was mixed with NhPV (25 μg/mL) or Suramin (25 μg/mL) and added to the 293T_ACE2 cells with SPΔC_G614-PVs simultaneously. In parallel, the same concentrations of SAD-S35 alone were used for comparison. The results show that 1.25 μg/ml of SAD-S35 alone only resulted in an approximately 25% decrease of infection. However, nearly 80% inhibitory effect was achieved when the same concentration of SAD-S35 was combined with NhPV (25μg/ml), or approximately 60% inhibitory effect was achieved when combined with Suramin (25μg/ml), while NhPV or Suramin alone only mediated approximately 50% or 38% inhibition, respectively (Fig 3B). All together, the results clearly indicate that a combination of NhPV or Suramin with SAD-S35 is able to more potently block SARS-CoV2 infection. By including a low dose of nAb, the amounts of NhPV or Suramin needed to achieve highly effective inhibition of SARS-CoV2 infection can be reduced.

Inhibitory effect of NhPV and Suramin on SARS-CoV-2 virus infection

Given that both NhPV and Suramin are able to block the SARS-CoV2-SP pseudovirus entry, we next tested whether these two drugs could block wild type SARS-CoV2 virus infection and virus-induced cytopathic effect in Vero cells. The wild type SARS-CoV-2 virus (hCoV- 19/Canada/ON-VIDO-01/2020) was used to infect Vero cells in the presence of different concentrations of NhPV or Suramin. Briefly, Vero cells were infected with SARS-CoV-2 (MOI of 0.01) in the presence of different concentrations of NhPV, or Suramin. After 72 hrs post-infection, as indicated in Fig 6, the SARS-CoV-2-induced cytopathic effects in Vero cells were monitored. Results showed that SARS-CoV-2 infection caused dramatic cytopathic effect (CPE) in Vero cells after 72 hrs post-infection, with cells displaying 100% CPE. Remarkably, in the presence of NhPV or Suramin (at 50 to 125 μg/ml), the SARS-CoV-2-induced cytopathic effect (CPE) was partially or completely inhibited in Vero cells (Fig 6A and 6B). Also, we directly monitored the inhibitory effects of NhPV and Suramin on SARS-CoV-2 virus infection by titrating the produced progeny viruses by TCID₅₀ assay. Results revealed that at 100 μg/ml, NhPV completely inhibited SARS-CoV-2 virus infection (Fig 6C), while Suramin significantly reduced SARS-CoV-2 virus replication at 200 μg/ml (Fig 6D). These results provide strong evidence that the presence of NhPV or Suramin is able to inhibit SARS-CoV-2 infection.

Download:

Fig 6. Inhibitory effect of NhPV and Suramin on SARS-CoV-2 infection-induced cytopathic effects.

Vero cells were infected with a wild type SARS-CoV-2 virus (hCoV- 19/Canada/ON-VIDO-01/2020) in the presence or absence of different concentrations of NhPV and Suramin. After 72 hrs pi., the SARS-CoV-2 infection-induced cytopathic effects in Vero cells were monitored. Error bars represent variation between triplicate samples, and the data of (A) and (B) are representative of results obtained in three independent experiments. Also, the supernatants from SARS-CoV-2 infected cultures in the presence of different concentrations of NhPV (C) or Suramin (D) were collected and the levels of progeny virus produced from infected cultures were titrated by TCID₅₀ assay in Vero cells. The results are the mean ±S.D. of duplicate samples, and the data are representative of results obtained in two independent experiments.

https://doi.org/10.1371/journal.pone.0251649.g006

Discussion

Because SARS-CoV-2 is classified as an aerosol biosafety level 3 (BSL-3) pathogen, the study of SARS-CoV-2 infection and the investigation of different anti-SARS-CoV-2 compounds required highly restricted BSL-3 containment. This condition has significantly limited the SARS-CoV-2-related research activities in microbiology laboratories. In this study, we established a highly sensitive SARS-CoV-2-SP pseudotyped HIV-based entry system, which encodes a Gaussia luciferase (Gluc) gene as a reporter (Fig 1B). Since Gluc can be secreted into the supernatant after being expressed in the infected cells, it is very sensitive and convenient for evaluating the level of SARS-CoV2-SP-mediated virus entry and may be used for anti-SARS-CoV2-SP compound screening in a BSL-2 environment.

Previous studies have revealed that the cytoplasmic tail (CT) of SARS SP contains a dibasic motif (KxHxx) that constitutes for an endoplasmic reticulum (ER) retrieval signal which retains the full-length SARS-S protein in the lumen of the ER-Golgi intermediate compartment (ERGIC) [40, 41]. Deletion of 17 aa at the carboxyl-terminal in the CT of SARS SP was able to increase SP transported to the surface of cells and substantially increased SARS SP-mediated cell-to-cell fusion [38]. In the SARS-CoV2-SP, there is also a dibasic motif (KxHxx) present in the CT (Fg 1A). In order to increase SARS-CoV2-SP incorporation into pseudovirions, we have deleted 17 aa at the CT of SARS-CoV2 SP and generated a SARS-CoV2 SPΔC expressor plasmid (Fig 1A(b)). Indeed, our data showed that a significantly higher level of SCoV2 SPΔC protein was present in the pseudovirus (Fig 1C), and induced remarkably efficient infection in 293T_ACE2 cells (Fig 1D). This observation clearly indicates that the dibasic motif in SARS-CoV-2 SP is functional and a deletion of 17 amino acids substantially increased incorporation of SP into SARS-CoV2-SP-PVs and enhance its infectivity. This information is also important for improving the design of SARS-CoV2-SP-based vaccine strategies.

Recent sequencing analyses found a SARS-CoV2 SP mutation, Aspartic acid (D) changed to Glycine (G) at aa position 614 in the S1 domain which was dominantly detected in April to May of 2020 isolates, indicating a transmission advantage over original SP D614 [14]. The following studies showed that SARS-CoV2_G614 SP mutant MLV pseudotyped viruses infected ACE2-expressing cells markedly more efficiently than those with SARS-CoV2_D614 [15, 42]. Consistently, we also observed the SARS-CoV2_G614ΔC-pseudotyped lentiviral particles enhanced the pseudotyped virus entry compared to the SP_D614ΔC-PVs (Fig 2E).

By using this SCoV2-SP- pseudovirus system, we have provided evidence for the first time that the NhPV can efficiently prevent infections mediated by both SARS-CoV2-SP_D614 and SARS-CoV2-SP_G614 pseudovirus infection in 293T_ACE2 cells (Fig 3) and significantly block the infection of the wild type SARS-CoV-2 in Vero cells (Fig 6). We also revealed that NhPV was able to directly interrupt the interaction of SARS-CoV2-SP and ACE2 receptor by in vitro ELISA assay (Fig 4C). Interestingly, the presence of NhPV at one hour post-infection is still able to efficiently inhibit SARS-Cov2-SP pseudovirus infection (Fig 4A), suggesting that NhPV may not only target SP/ACE2 binding, but may also act on the following fusion step(s). Overall, our results provide convincing evidence for NhPV as a potential blocking agent against SARS-CoV-2 infection. In agreement with a recent study [32] that Suramin inhibited SARS-CoV-2 virus infection by acting the early stage, we further provide evidence that Suramin is able to directly block SARS-CoV-2 SP-ACE2 interaction (Fig 4D), inhibit different SARS-CoV-2 SP variants mediated virus entry (Figs 3–5) and SARS-CoV-2 infection induced cytopathic effects (Fig 6B).

Another interesting observation in this study is that the combination of NhPV or Suramin with anti-SARS-CoV-2 neutralizing antibody (nAb) could enhance their anti-SARS-CoV-2 activity. The nAbs have great potential to be used as a preventing agent in blocking SARS-CoV-2 infection [43]. However, one disadvantage of using nAb as an anti-SARS-CoV-2 agent is its source limitation. Therefore, the finding of the synergistic effect of a combination of nAb with other agents, such as NhPV or Suramin is beneficial for (i) similar efficiencies would be achieved by using reduced amounts of antibody and NhPV or Suramin, (ii) the combination of nAb and NhPV/suramin will reduce the likelihood of viral resistance. Whether these enhanced effects might be due to a combined effect through their different binding mechanisms still needs to be investigated.

The effectiveness of NhPV and/or Suramin against SARS-CoV-2 infection in vivo remains to be investigated. Our findings could be further validated in an appropriate animal model and clinical trials for prevention of COVID-19. Since SARS-CoV-2 infection initiates in the respiratory tract [44], the use of NhPV and/or Suramin as nasopharynx agents (Nasal spray) to prevent initial SARS-CoV-2 infection and transmission in the respiratory tract will be a particularly attractive strategy, and will require further efficacy studies. Overall, we demonstrated that NhPV and Suramin possess an anti-SARS-CoV-2 entry inhibitor activity and functions at least partially by interrupting SARS-CoV-2 SP binding to its receptor. Additional in vivo safety and protection studies will facilitate its application as an option to help control the ongoing SARS-CoV-2 pandemic.

Supporting information

S1 Raw images.

https://doi.org/10.1371/journal.pone.0251649.s001

(PDF)

Acknowledgments

The authors would like to thank Dr. Gary R. Whittaker from the College of Veterinary Medicine, Cornell University for kindly providing the SARS-CoV S.P. expressing plasmids (pcDNA-SARS-S), pCMV-MLVgagpol MLV plasmid, and pTG-Luc MLV transfer vector.

References

1. Li Q, Guan X, Wu P, Wang X, Zhou L, et al. (2020) Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia. N Engl J Med 382: 1199–1207. pmid:31995857
- View Article
- PubMed/NCBI
- Google Scholar
2. Abdollahi E, Champredon D, Langley JM, Galvani AP, Moghadas SM (2020) Temporal estimates of case-fatality rate for COVID-19 outbreaks in Canada and the United States. CMAJ 192: E666–E670. pmid:32444481
- View Article
- PubMed/NCBI
- Google Scholar
3. Baud D, Qi X, Nielsen-Saines K, Musso D, Pomar L, et al. (2020) Real estimates of mortality following COVID-19 infection. Lancet Infect Dis 20: 773. pmid:32171390
- View Article
- PubMed/NCBI
- Google Scholar
4. Organization WH (2020) Estimating mortality from COVID-19 Scientific brief, 4 August 2020. https://wwwwhoint/publications/i/item/WHO-2019-nCoV-Sci-Brief-Mortality-20201.
- View Article
- Google Scholar
5. Zhang Y-Z (2020) Severe acute respiratory syndrome coronavirus 2 isolate Wuhan-Hu-1, complete genome. GenBank: MN 9089473.
6. Zhou Z, Kang H, Li S, Zhao X (2020) Understanding the neurotropic characteristics of SARS-CoV-2: from neurological manifestations of COVID-19 to potential neurotropic mechanisms. J Neurol 267: 2179–2184. pmid:32458193
- View Article
- PubMed/NCBI
- Google Scholar
7. Ahmed MU, Hanif M, Ali MJ, Haider MA, Kherani D, et al. (2020) Neurological Manifestations of COVID-19 (SARS-CoV-2): A Review. Front Neurol 11: 518. pmid:32574248
- View Article
- PubMed/NCBI
- Google Scholar
8. Kim GU, Kim MJ, Ra SH, Lee J, Bae S, et al. (2020) Clinical characteristics of asymptomatic and symptomatic patients with mild COVID-19. Clin Microbiol Infect 26: 948 e941–948 e943. pmid:32360780
- View Article
- PubMed/NCBI
- Google Scholar
9. Lin L, Jiang X, Zhang Z, Huang S, Zhang Z, et al. (2020) Gastrointestinal symptoms of 95 cases with SARS-CoV-2 infection. Gut 69: 997–1001. pmid:32241899
- View Article
- PubMed/NCBI
- Google Scholar
10. Raj VS, Osterhaus ADME, Fouchier RAM, Haagmans BL (2014) MERS: emergence of a novel human coronavirus. Current opinion in virology 5: 58–62. pmid:24584035
- View Article
- PubMed/NCBI
- Google Scholar
11. Su S, Wong G, Shi W, Liu J, Lai ACK, et al. (2016) Epidemiology, genetic recombination, and pathogenesis of coronaviruses. Trends in microbiology 24: 490–502. pmid:27012512
- View Article
- PubMed/NCBI
- Google Scholar
12. Lu R, Zhao X, Li J, Niu P, Yang B, et al. (2020) Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet Jan 30 S0140-6736(0120)30251-30258. pmid:32007145
- View Article
- PubMed/NCBI
- Google Scholar
13. Jaimes JA, Millet JK, Whittaker GR (2020) Proteolytic Cleavage of the SARS-CoV-2 Spike Protein and the Role of the Novel S1/S2 Site. iScience 23: 101212. pmid:32512386
- View Article
- PubMed/NCBI
- Google Scholar
14. Korber B. FW, Gnanakaran S., Yoon H., Theiler J., Abfalterer W., Foley B., et al. (2020) Spike mutation pipeline reveals the emergence of a more transmissible form of SARS-CoV-2. bioRxiv https://doi.org/10.1101/2020.04.29.069054.
- View Article
- Google Scholar
15. Lizhou Zhang CBJ, Mou Huihui, Ojha Amrita, Rangarajan Erumbi S, Izard Tina, Farzan Michael, Choe Hyeryun (2020) The D614G mutation in the SARS-CoV-2 spike protein reduces S1 shedding and increases infectivity bioRxiv 06.12.: 148726. pmid:32587973
- View Article
- PubMed/NCBI
- Google Scholar
16. Cao B, Wang Y, Wen D, Liu W, Wang J, et al. (2020) A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19. N Engl J Med 382: 1787–1799. pmid:32187464
- View Article
- PubMed/NCBI
- Google Scholar
17. Grein J, Ohmagari N, Shin D, Diaz G, Asperges E, et al. (2020) Compassionate use of remdesivir for patients with severe Covid-19. New England Journal of Medicine 382: 2327–2336. pmid:32275812
- View Article
- PubMed/NCBI
- Google Scholar
18. Zhang L, Lin D, Sun X, Curth U, Drosten C, et al. (2020) Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved Î±-ketoamide inhibitors. Science 368: 409–412. pmid:32198291
- View Article
- PubMed/NCBI
- Google Scholar
19. Huang D, Yu H, Wang T, Yang H, Yao R, et al. (2020) Efficacy and safety of umifenovir for coronavirus disease 2019 (COVID-19): A systematic review and meta-analysis. J Med Virol. pmid:32617989
- View Article
- PubMed/NCBI
- Google Scholar
20. Wang M, Cao R, Zhang L, Yang X, Liu J, et al. (2020) Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res 30: 269–271. pmid:32020029
- View Article
- PubMed/NCBI
- Google Scholar
21. Hussain S, Xie YJ, Li D, Malik SI, Hou JC, et al. (2020) Current strategies against COVID-19. Chin Med 15: 70. pmid:32665783
- View Article
- PubMed/NCBI
- Google Scholar
22. Park S-J, Yu K-M, Kim Y-I, Kim S-M, Kim E-H, et al. (2020) Antiviral Efficacies of FDA-Approved Drugs against SARS-CoV-2 Infection in Ferrets. Mbio 11. pmid:32444382
- View Article
- PubMed/NCBI
- Google Scholar
23. Zheng M (1990) [Experimental study of 472 herbs with antiviral action against the herpes simplex virus]. Zhong xi yi jie he za zhi = Chinese journal of modern developments in traditional medicine/Zhongguo Zhong xi yi jie he yan jiu hui (chou), Zhong yi yan jiu yuan, zhu ban 10: 39–41, 36. pmid:2161714
- View Article
- PubMed/NCBI
- Google Scholar
24. Yao XJ, Wainberg MA, Parniak MA (1992) Mechanism of inhibition of HIV-1 infection in vitro by purified extract of Prunella vulgaris. Virology 187: 56–62. pmid:1371029
- View Article
- PubMed/NCBI
- Google Scholar
25. Zhang X, Ao Z, Bello A, Ran X, Liu S, et al. (2016) Characterization of the inhibitory effect of an extract of Prunella vulgaris on Ebola virus glycoprotein (GP)-mediated virus entry and infection. Antiviral Res 127: 20–31. pmid:26778707
- View Article
- PubMed/NCBI
- Google Scholar
26. Liu S, Jiang S, Wu Z, Lv L, Zhang J, et al. (2002) Identification of inhibitors of the HIV-1 gp41 six-helix bundle formation from extracts of Chinese medicinal herbs Prunella vulgaris and Rhizoma cibotte. Life Sci 71: 1779–1791. pmid:12151056
- View Article
- PubMed/NCBI
- Google Scholar
27. Xu HX, Lee SH, Lee SF, White RL, Blay J (1999) Isolation and characterization of an anti-HSV polysaccharide from Prunella vulgaris. Antiviral Res 44: 43–54. pmid:10588332
- View Article
- PubMed/NCBI
- Google Scholar
28. De Clercq E (1987) Suramin in the treatment of AIDS: mechanism of action. Antiviral Res 7: 1–10. pmid:2432836
- View Article
- PubMed/NCBI
- Google Scholar
29. Cheson BD, Levine AM, Mildvan D, Kaplan LD, Wolfe P, et al. (1987) Suramin therapy in AIDS and related disorders. Report of the US Suramin Working Group. JAMA 258: 1347–1351. pmid:3650339
- View Article
- PubMed/NCBI
- Google Scholar
30. Yao XJ, Wainberg MA, Pollak M (1991) The inhibitory effects of suramin on HIV-1 are attenuated in the presence of albumin. AIDS 5: 1389–1391. pmid:1768390
- View Article
- PubMed/NCBI
- Google Scholar
31. Kuo SC, Wang YM, Ho YJ, Chang TY, Lai ZZ, et al. (2016) Suramin treatment reduces chikungunya pathogenesis in mice. Antiviral Res 134: 89–96. pmid:27577529
- View Article
- PubMed/NCBI
- Google Scholar
32. Clarisse Salgado Benvindo da Silva MT, Tas Ali, Ogando Natacha S., Bredenbeek Peter J., Ninaber Dennis K., Wang Ying, et al. (2020) Suramin inhibits SARS-CoV-2 infection in cell culture by interfering 1 with early steps of the replication cycle. bioRxiv May: https://doi.org/10.1101/2020.1105.1106.081968.
- View Article
- Google Scholar
33. Ao Z, Huang J, Tan X, Wang X, Tian T, et al. (2016) Characterization of the single cycle replication of HIV-1 expressing Gaussia luciferase in human PBMCs, macrophages, and in CD4(+) T cell-grafted nude mouse. J Virol Methods 228: 95–102. pmid:26640121
- View Article
- PubMed/NCBI
- Google Scholar
34. Qiu X, Alimonti JB, Melito PL, Fernando L, Ströher U, et al. (2011) Characterization of Zaire ebolavirus glycoprotein-specific monoclonal antibodies. Clinical immunology 141: 218–227. pmid:21925951
- View Article
- PubMed/NCBI
- Google Scholar
35. Ao Z, Huang G, Yao H, Xu Z, Labine M, et al. (2007) Interaction of human immunodeficiency virus type 1 integrase with cellular nuclear import receptor importin 7 and its impact on viral replication. Journal of Biological Chemistry 282: 13456–13467. pmid:17360709
- View Article
- PubMed/NCBI
- Google Scholar
36. Chen L, Ao Z, Jayappa KD, Kobinger G, Liu S, et al. (2013) Characterization of antiviral activity of benzamide derivative AH0109 against HIV-1 infection. Antimicrob Agents Chemother 57: 3547–3554. pmid:23669388
- View Article
- PubMed/NCBI
- Google Scholar
37. Millet JK, Tang T, Nathan L, Jaimes JA, Hsu HL, et al. (2019) Production of Pseudotyped Particles to Study Highly Pathogenic Coronaviruses in a Biosafety Level 2 Setting. J Vis Exp.
- View Article
- Google Scholar
38. Petit CM, Melancon JM, Chouljenko VN, Colgrove R, Farzan M, et al. (2005) Genetic analysis of the SARS-coronavirus spike glycoprotein functional domains involved in cell-surface expression and cell-to-cell fusion. Virology 341: 215–230. pmid:16099010
- View Article
- PubMed/NCBI
- Google Scholar
39. Jarek Juraszek LR, Blokland Sven, Bouchier Pascale, Voorzaat Richard, Ritschel Tina, Bakkers Mark J.G., et al. (2020) Stabilizing the Closed SARS-CoV-2 Spike Trimer bioRxiv https://doi.org/10.1101/2020.07.10.197814doi:: July 10.
- View Article
- Google Scholar
40. Sadasivan J, Singh M, Sarma JD (2017) Cytoplasmic tail of coronavirus spike protein has intracellular targeting signals. J Biosci 42: 231–244. pmid:28569247
- View Article
- PubMed/NCBI
- Google Scholar
41. McBride CE, Li J, Machamer CE (2007) The cytoplasmic tail of the severe acute respiratory syndrome coronavirus spike protein contains a novel endoplasmic reticulum retrieval signal that binds COPI and promotes interaction with membrane protein. J Virol 81: 2418–2428. pmid:17166901
- View Article
- PubMed/NCBI
- Google Scholar
42. Jie Hu C-LH, Qing-Zhu Gao, Gui-Ji Zhang, Xiao-Xia Cao, Quan-Xin Long, Hai-Jun Deng, et al. (2020) The D614G mutation of SARS-CoV-2 spike protein enhances viral infectivity 1 and decreases neutralization sensitivity to individual convalescent sera bioRxiv https://doi.org/10.1101/2020.06.20.161323doi:.
- View Article
- Google Scholar
43. Jiang S-B, Hillyer C, L-Y D (2020) Neutralizing Antibodies against SARS-CoV-2 and Other Human Coronaviruses. Trends in immunology 41: 355–359. pmid:32249063
- View Article
- PubMed/NCBI
- Google Scholar
44. Wolfel R, Corman VM, Guggemos W, Seilmaier M, Zange S, et al. (2020) Virological assessment of hospitalized patients with COVID-2019. Nature 581: 465–469. pmid:32235945
- View Article
- PubMed/NCBI
- Google Scholar

[ref1] 1. Li Q, Guan X, Wu P, Wang X, Zhou L, et al. (2020) Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia. N Engl J Med 382: 1199–1207. pmid:31995857
View Article
PubMed/NCBI
Google Scholar

[2] View Article

[3] PubMed/NCBI

[4] Google Scholar

[ref2] 2. Abdollahi E, Champredon D, Langley JM, Galvani AP, Moghadas SM (2020) Temporal estimates of case-fatality rate for COVID-19 outbreaks in Canada and the United States. CMAJ 192: E666–E670. pmid:32444481
View Article
PubMed/NCBI
Google Scholar

[6] View Article

[7] PubMed/NCBI

[8] Google Scholar

[ref3] 3. Baud D, Qi X, Nielsen-Saines K, Musso D, Pomar L, et al. (2020) Real estimates of mortality following COVID-19 infection. Lancet Infect Dis 20: 773. pmid:32171390
View Article
PubMed/NCBI
Google Scholar

[10] View Article

[11] PubMed/NCBI

[12] Google Scholar

[ref4] 4. Organization WH (2020) Estimating mortality from COVID-19 Scientific brief, 4 August 2020. https://wwwwhoint/publications/i/item/WHO-2019-nCoV-Sci-Brief-Mortality-20201.
View Article
Google Scholar

[14] View Article

[15] Google Scholar

[ref5] 5. Zhang Y-Z (2020) Severe acute respiratory syndrome coronavirus 2 isolate Wuhan-Hu-1, complete genome. GenBank: MN 9089473.

[ref6] 6. Zhou Z, Kang H, Li S, Zhao X (2020) Understanding the neurotropic characteristics of SARS-CoV-2: from neurological manifestations of COVID-19 to potential neurotropic mechanisms. J Neurol 267: 2179–2184. pmid:32458193
View Article
PubMed/NCBI
Google Scholar

[18] View Article

[19] PubMed/NCBI

[20] Google Scholar

[ref7] 7. Ahmed MU, Hanif M, Ali MJ, Haider MA, Kherani D, et al. (2020) Neurological Manifestations of COVID-19 (SARS-CoV-2): A Review. Front Neurol 11: 518. pmid:32574248
View Article
PubMed/NCBI
Google Scholar

[22] View Article

[23] PubMed/NCBI

[24] Google Scholar

[ref8] 8. Kim GU, Kim MJ, Ra SH, Lee J, Bae S, et al. (2020) Clinical characteristics of asymptomatic and symptomatic patients with mild COVID-19. Clin Microbiol Infect 26: 948 e941–948 e943. pmid:32360780
View Article
PubMed/NCBI
Google Scholar

[26] View Article

[27] PubMed/NCBI

[28] Google Scholar

[ref9] 9. Lin L, Jiang X, Zhang Z, Huang S, Zhang Z, et al. (2020) Gastrointestinal symptoms of 95 cases with SARS-CoV-2 infection. Gut 69: 997–1001. pmid:32241899
View Article
PubMed/NCBI
Google Scholar

[30] View Article

[31] PubMed/NCBI

[32] Google Scholar

[ref10] 10. Raj VS, Osterhaus ADME, Fouchier RAM, Haagmans BL (2014) MERS: emergence of a novel human coronavirus. Current opinion in virology 5: 58–62. pmid:24584035
View Article
PubMed/NCBI
Google Scholar

[34] View Article

[35] PubMed/NCBI

[36] Google Scholar

[ref11] 11. Su S, Wong G, Shi W, Liu J, Lai ACK, et al. (2016) Epidemiology, genetic recombination, and pathogenesis of coronaviruses. Trends in microbiology 24: 490–502. pmid:27012512
View Article
PubMed/NCBI
Google Scholar

[38] View Article

[39] PubMed/NCBI

[40] Google Scholar

[ref12] 12. Lu R, Zhao X, Li J, Niu P, Yang B, et al. (2020) Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet Jan 30 S0140-6736(0120)30251-30258. pmid:32007145
View Article
PubMed/NCBI
Google Scholar

[42] View Article

[43] PubMed/NCBI

[44] Google Scholar

[ref13] 13. Jaimes JA, Millet JK, Whittaker GR (2020) Proteolytic Cleavage of the SARS-CoV-2 Spike Protein and the Role of the Novel S1/S2 Site. iScience 23: 101212. pmid:32512386
View Article
PubMed/NCBI
Google Scholar

[46] View Article

[47] PubMed/NCBI

[48] Google Scholar

[ref14] 14. Korber B. FW, Gnanakaran S., Yoon H., Theiler J., Abfalterer W., Foley B., et al. (2020) Spike mutation pipeline reveals the emergence of a more transmissible form of SARS-CoV-2. bioRxiv https://doi.org/10.1101/2020.04.29.069054.
View Article
Google Scholar

[50] View Article

[51] Google Scholar

[ref15] 15. Lizhou Zhang CBJ, Mou Huihui, Ojha Amrita, Rangarajan Erumbi S, Izard Tina, Farzan Michael, Choe Hyeryun (2020) The D614G mutation in the SARS-CoV-2 spike protein reduces S1 shedding and increases infectivity bioRxiv 06.12.: 148726. pmid:32587973
View Article
PubMed/NCBI
Google Scholar

[53] View Article

[54] PubMed/NCBI

[55] Google Scholar

[ref16] 16. Cao B, Wang Y, Wen D, Liu W, Wang J, et al. (2020) A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19. N Engl J Med 382: 1787–1799. pmid:32187464
View Article
PubMed/NCBI
Google Scholar

[57] View Article

[58] PubMed/NCBI

[59] Google Scholar

[ref17] 17. Grein J, Ohmagari N, Shin D, Diaz G, Asperges E, et al. (2020) Compassionate use of remdesivir for patients with severe Covid-19. New England Journal of Medicine 382: 2327–2336. pmid:32275812
View Article
PubMed/NCBI
Google Scholar

[61] View Article

[62] PubMed/NCBI

[63] Google Scholar

[ref18] 18. Zhang L, Lin D, Sun X, Curth U, Drosten C, et al. (2020) Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved Î±-ketoamide inhibitors. Science 368: 409–412. pmid:32198291
View Article
PubMed/NCBI
Google Scholar

[65] View Article

[66] PubMed/NCBI

[67] Google Scholar

[ref19] 19. Huang D, Yu H, Wang T, Yang H, Yao R, et al. (2020) Efficacy and safety of umifenovir for coronavirus disease 2019 (COVID-19): A systematic review and meta-analysis. J Med Virol. pmid:32617989
View Article
PubMed/NCBI
Google Scholar

[69] View Article

[70] PubMed/NCBI

[71] Google Scholar

[ref20] 20. Wang M, Cao R, Zhang L, Yang X, Liu J, et al. (2020) Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res 30: 269–271. pmid:32020029
View Article
PubMed/NCBI
Google Scholar

[73] View Article

[74] PubMed/NCBI

[75] Google Scholar

[ref21] 21. Hussain S, Xie YJ, Li D, Malik SI, Hou JC, et al. (2020) Current strategies against COVID-19. Chin Med 15: 70. pmid:32665783
View Article
PubMed/NCBI
Google Scholar

[77] View Article

[78] PubMed/NCBI

[79] Google Scholar

[ref22] 22. Park S-J, Yu K-M, Kim Y-I, Kim S-M, Kim E-H, et al. (2020) Antiviral Efficacies of FDA-Approved Drugs against SARS-CoV-2 Infection in Ferrets. Mbio 11. pmid:32444382
View Article
PubMed/NCBI
Google Scholar

[81] View Article

[82] PubMed/NCBI

[83] Google Scholar

[ref23] 23. Zheng M (1990) [Experimental study of 472 herbs with antiviral action against the herpes simplex virus]. Zhong xi yi jie he za zhi = Chinese journal of modern developments in traditional medicine/Zhongguo Zhong xi yi jie he yan jiu hui (chou), Zhong yi yan jiu yuan, zhu ban 10: 39–41, 36. pmid:2161714
View Article
PubMed/NCBI
Google Scholar

[85] View Article

[86] PubMed/NCBI

[87] Google Scholar

[ref24] 24. Yao XJ, Wainberg MA, Parniak MA (1992) Mechanism of inhibition of HIV-1 infection in vitro by purified extract of Prunella vulgaris. Virology 187: 56–62. pmid:1371029
View Article
PubMed/NCBI
Google Scholar

[89] View Article

[90] PubMed/NCBI

[91] Google Scholar

[ref25] 25. Zhang X, Ao Z, Bello A, Ran X, Liu S, et al. (2016) Characterization of the inhibitory effect of an extract of Prunella vulgaris on Ebola virus glycoprotein (GP)-mediated virus entry and infection. Antiviral Res 127: 20–31. pmid:26778707
View Article
PubMed/NCBI
Google Scholar

[93] View Article

[94] PubMed/NCBI

[95] Google Scholar

[ref26] 26. Liu S, Jiang S, Wu Z, Lv L, Zhang J, et al. (2002) Identification of inhibitors of the HIV-1 gp41 six-helix bundle formation from extracts of Chinese medicinal herbs Prunella vulgaris and Rhizoma cibotte. Life Sci 71: 1779–1791. pmid:12151056
View Article
PubMed/NCBI
Google Scholar

[97] View Article

[98] PubMed/NCBI

[99] Google Scholar

[ref27] 27. Xu HX, Lee SH, Lee SF, White RL, Blay J (1999) Isolation and characterization of an anti-HSV polysaccharide from Prunella vulgaris. Antiviral Res 44: 43–54. pmid:10588332
View Article
PubMed/NCBI
Google Scholar

[101] View Article

[102] PubMed/NCBI

[103] Google Scholar

[ref28] 28. De Clercq E (1987) Suramin in the treatment of AIDS: mechanism of action. Antiviral Res 7: 1–10. pmid:2432836
View Article
PubMed/NCBI
Google Scholar

[105] View Article

[106] PubMed/NCBI

[107] Google Scholar

[ref29] 29. Cheson BD, Levine AM, Mildvan D, Kaplan LD, Wolfe P, et al. (1987) Suramin therapy in AIDS and related disorders. Report of the US Suramin Working Group. JAMA 258: 1347–1351. pmid:3650339
View Article
PubMed/NCBI
Google Scholar

[109] View Article

[110] PubMed/NCBI

[111] Google Scholar

[ref30] 30. Yao XJ, Wainberg MA, Pollak M (1991) The inhibitory effects of suramin on HIV-1 are attenuated in the presence of albumin. AIDS 5: 1389–1391. pmid:1768390
View Article
PubMed/NCBI
Google Scholar

[113] View Article

[114] PubMed/NCBI

[115] Google Scholar

[ref31] 31. Kuo SC, Wang YM, Ho YJ, Chang TY, Lai ZZ, et al. (2016) Suramin treatment reduces chikungunya pathogenesis in mice. Antiviral Res 134: 89–96. pmid:27577529
View Article
PubMed/NCBI
Google Scholar

[117] View Article

[118] PubMed/NCBI

[119] Google Scholar

[ref32] 32. Clarisse Salgado Benvindo da Silva MT, Tas Ali, Ogando Natacha S., Bredenbeek Peter J., Ninaber Dennis K., Wang Ying, et al. (2020) Suramin inhibits SARS-CoV-2 infection in cell culture by interfering 1 with early steps of the replication cycle. bioRxiv May: https://doi.org/10.1101/2020.1105.1106.081968.
View Article
Google Scholar

[121] View Article

[122] Google Scholar

[ref33] 33. Ao Z, Huang J, Tan X, Wang X, Tian T, et al. (2016) Characterization of the single cycle replication of HIV-1 expressing Gaussia luciferase in human PBMCs, macrophages, and in CD4(+) T cell-grafted nude mouse. J Virol Methods 228: 95–102. pmid:26640121
View Article
PubMed/NCBI
Google Scholar

[124] View Article

[125] PubMed/NCBI

[126] Google Scholar

[ref34] 34. Qiu X, Alimonti JB, Melito PL, Fernando L, Ströher U, et al. (2011) Characterization of Zaire ebolavirus glycoprotein-specific monoclonal antibodies. Clinical immunology 141: 218–227. pmid:21925951
View Article
PubMed/NCBI
Google Scholar

[128] View Article

[129] PubMed/NCBI

[130] Google Scholar

[ref35] 35. Ao Z, Huang G, Yao H, Xu Z, Labine M, et al. (2007) Interaction of human immunodeficiency virus type 1 integrase with cellular nuclear import receptor importin 7 and its impact on viral replication. Journal of Biological Chemistry 282: 13456–13467. pmid:17360709
View Article
PubMed/NCBI
Google Scholar

[132] View Article

[133] PubMed/NCBI

[134] Google Scholar

[ref36] 36. Chen L, Ao Z, Jayappa KD, Kobinger G, Liu S, et al. (2013) Characterization of antiviral activity of benzamide derivative AH0109 against HIV-1 infection. Antimicrob Agents Chemother 57: 3547–3554. pmid:23669388
View Article
PubMed/NCBI
Google Scholar

[136] View Article

[137] PubMed/NCBI

[138] Google Scholar

[ref37] 37. Millet JK, Tang T, Nathan L, Jaimes JA, Hsu HL, et al. (2019) Production of Pseudotyped Particles to Study Highly Pathogenic Coronaviruses in a Biosafety Level 2 Setting. J Vis Exp.
View Article
Google Scholar

[140] View Article

[141] Google Scholar

[ref38] 38. Petit CM, Melancon JM, Chouljenko VN, Colgrove R, Farzan M, et al. (2005) Genetic analysis of the SARS-coronavirus spike glycoprotein functional domains involved in cell-surface expression and cell-to-cell fusion. Virology 341: 215–230. pmid:16099010
View Article
PubMed/NCBI
Google Scholar

[143] View Article

[144] PubMed/NCBI

[145] Google Scholar

[ref39] 39. Jarek Juraszek LR, Blokland Sven, Bouchier Pascale, Voorzaat Richard, Ritschel Tina, Bakkers Mark J.G., et al. (2020) Stabilizing the Closed SARS-CoV-2 Spike Trimer bioRxiv https://doi.org/10.1101/2020.07.10.197814doi:: July 10.
View Article
Google Scholar

[147] View Article

[148] Google Scholar

[ref40] 40. Sadasivan J, Singh M, Sarma JD (2017) Cytoplasmic tail of coronavirus spike protein has intracellular targeting signals. J Biosci 42: 231–244. pmid:28569247
View Article
PubMed/NCBI
Google Scholar

[150] View Article

[151] PubMed/NCBI

[152] Google Scholar

[ref41] 41. McBride CE, Li J, Machamer CE (2007) The cytoplasmic tail of the severe acute respiratory syndrome coronavirus spike protein contains a novel endoplasmic reticulum retrieval signal that binds COPI and promotes interaction with membrane protein. J Virol 81: 2418–2428. pmid:17166901
View Article
PubMed/NCBI
Google Scholar

[154] View Article

[155] PubMed/NCBI

[156] Google Scholar

[ref42] 42. Jie Hu C-LH, Qing-Zhu Gao, Gui-Ji Zhang, Xiao-Xia Cao, Quan-Xin Long, Hai-Jun Deng, et al. (2020) The D614G mutation of SARS-CoV-2 spike protein enhances viral infectivity 1 and decreases neutralization sensitivity to individual convalescent sera bioRxiv https://doi.org/10.1101/2020.06.20.161323doi:.
View Article
Google Scholar

[158] View Article

[159] Google Scholar

[ref43] 43. Jiang S-B, Hillyer C, L-Y D (2020) Neutralizing Antibodies against SARS-CoV-2 and Other Human Coronaviruses. Trends in immunology 41: 355–359. pmid:32249063
View Article
PubMed/NCBI
Google Scholar

[161] View Article

[162] PubMed/NCBI

[163] Google Scholar

[ref44] 44. Wolfel R, Corman VM, Guggemos W, Seilmaier M, Zange S, et al. (2020) Virological assessment of hospitalized patients with COVID-2019. Nature 581: 465–469. pmid:32235945
View Article
PubMed/NCBI
Google Scholar

[165] View Article

[166] PubMed/NCBI

[167] Google Scholar

Figures

Abstract

Introduction

Materials & methods

Plasmid constructs

Cell culture, antibodies and chemicals

Preparation and purification of herb extracts of Natural herb Prunella vulgaris (NhPV)

Virus production, infection and inhibition experiments

COVID-19 spike protein-ACE2 binding assay

Western blot (WB) analyses

Cytotoxicity assay

Statistical analysis

Results

Generation of a SARS-CoV-2 SP-pseudotyped HIV-1-based entry system

SARS-CoV-2 SP G416 variant exhibited more efficient virus entry

Evaluation of NhPV and Suramin for blocking SARS-CoV2-SP-mediated virus entry

Mechanistic analyses of actions of NhPV and Suramin against SARS-CoV-2-SP-mediated virus entry

Combination of NhPV and anti-SARS-CoV-2 neutralizing antibody (SAD-S35) mediated more potent blocking effect against SARS-CoV2-SP-PVs

Inhibitory effect of NhPV and Suramin on SARS-CoV-2 virus infection

Discussion

Supporting information

S1 Raw images.

Acknowledgments

References